Criscione Vincent D, Weinstock Martin A, Naylor Mark F, Luque Claudia, Eide Melody J, Bingham Stephen F
Dermatoepidemiology Unit, Veterans Affairs Medical Center, Providence, Rhode Island 02908-4799, USA.
Cancer. 2009 Jun 1;115(11):2523-30. doi: 10.1002/cncr.24284.
Actinic keratoses (AKs) are established as direct precursors of squamous cell carcinoma (SCC), but there is significant controversy regarding the rate at which AKs progress to SCC. The authors of this report studied a high-risk population to estimate the risk of progression of AK to SCC and to basal cell carcinoma (BCC) and the risk of spontaneous regression of untreated AKs.
Data were obtained from participants in the Department of Veterans Affairs Topical Tretinoin Chemoprevention Trial. Participants were examined every 6 months for up to 6 years. At each examination, the locations on the face and ears of clinically diagnosed AKs and lesions scheduled for biopsy were marked, and high-resolution digital photographs were taken. These photographs were used later to map and track the presence, absence, or biopsy of each AK across visits.
In total, 7784 AKs were identified on the face and ears of 169 participants. The risk of progression of AK to primary SCC (invasive or in situ) was 0.60% at 1 year and 2.57% at 4 years. Approximately 65% of all primary SCCs and 36% of all primary BCCs diagnosed in the study cohort arose in lesions that previously were diagnosed clinically as AKs. The majority of AKs (55%) that were followed clinically were not present at the 1-year follow-up, and the majority (70%) were not present at the 5-year follow-up.
In the current study, the authors quantified the malignant potential of clinically diagnosed AKs for both SCC and BCC, although many did not persist, and the results suggested that AKs may play a greater role in the overall burden of keratinocyte carcinomas than previously documented.
光化性角化病(AK)已被确认为鳞状细胞癌(SCC)的直接前驱病变,但关于AK进展为SCC的速率存在重大争议。本报告的作者研究了高危人群,以评估AK进展为SCC和基底细胞癌(BCC)的风险以及未经治疗的AK自发消退的风险。
数据来自退伍军人事务部外用维甲酸化学预防试验的参与者。参与者每6个月接受一次检查,最长持续6年。每次检查时,标记临床诊断的AK和计划活检的病变在面部和耳部的位置,并拍摄高分辨率数码照片。这些照片随后用于在各次就诊时绘制和追踪每个AK的存在、消失或活检情况。
总共在169名参与者的面部和耳部识别出7784个AK。AK进展为原发性SCC(浸润性或原位)的风险在1年时为0.60%,在4年时为2.57%。在研究队列中诊断的所有原发性SCC中,约65%以及所有原发性BCC中36%起源于先前临床诊断为AK的病变。临床上随访的大多数AK(55%)在1年随访时已不存在,大多数(70%)在5年随访时已不存在。
在当前研究中,作者量化了临床诊断的AK发展为SCC和BCC的恶性潜能,尽管许多AK并未持续存在,结果表明AK在角质形成细胞癌的总体负担中可能比先前记录的发挥更大作用。